Cucurbit[7]uril-adamantane (CB7-Adma) pre-targeting platform licensed from Stony Brook University; two-step antibody-then-radionuclide delivery system targeting cancer-specific proteins; preclinical optimization underway

Biotech Distilled coverage (11)

2026-05-22 UPDATE: Perspective Therapeutics (CATX) - The ASCO Preview Quietly Resurrects VMT01 🔒 Paid
2026-05-12 UPDATE: Perspective Therapeutics (CATX) - Q1 Drops Three Quiet Tells 🔒 Paid
2026-04-27 UPDATE: Perspective Therapeutics (CATX) - CATX Drops AACR Data 🔒 Paid
2026-04-05 UPDATE: Perspective Therapeutics (CATX) Dropped a Stealth De-Risking Clue Ahead of AACR 🔒 Paid
2026-03-21 UPDATE: Perspective Therapeutics (CATX) - The Next Catalyst is Here 🔒 Paid
2026-03-15 UPDATE: The CATX Institutional Land Grab Continues 🔒 Paid
2026-02-14 UPDATE: Perspective Therapeutics (CATX) - The Smart Money Stampede Continues 🔒 Paid
2026-02-07 UPDATE: Perspective Therapeutics (CATX) Just Cleared the Deck (And Smart Money Bought the Dip) 🔒 Paid
2026-01-13 UPDATE: Why Did Perspective Therapeutics (CATX) Just Dropped 15% (And Why It Could Be Buying Opportunity)? 🔒 Paid
2026-01-10 UPDATE: Perspective Therapeutics (CATX) Drops an Alpha Hammer at ASCO-GI 🔒 Paid
2026-01-04 Perspective Therapeutics (CATX): Scientific Deep Dive for VMT-α-NET and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.